2016至2023年美国毒物中心报告的幼儿阿片类暴露趋势
该回顾性研究分析2016至2023年美国毒物中心报告的34,632例1月龄至6岁患儿单物质阿片暴露。暴露报告总数下降57.5%(r=-0.96;P<0.001),但死亡和严重效应绝对增加300%(r=0.96;P<0.001),轻微/无效应/未随访/无法随访下降66.2%(r=-0.99;P<0.001)。丁丙诺啡最常见(23.4%),与美沙酮均与严重效应风险增加相关(OR 1.93和14.98,均P<0.001);海洛因、芬太尼及合成非药品类阿片报告绝对增加512%(r=0.92;P<0.001),且与严重效应相关(OR 20.1;P<0.001)。作者认为暴露下降可能因报告不足而夸大,但仍强调加强中毒预防策略的必要性。
要点
- 34,632例1月龄至6岁患儿单物质阿片暴露中96.7%为意外暴露,中位年龄2.0岁(IQR 1.33-3.0岁)。
- 暴露报告总数下降57.5%(r=-0.96;P<0.001),但死亡和严重效应绝对增加300%(r=0.96;P<0.001)。
- 丁丙诺啡占报告暴露的23.4%,与严重效应风险增加相关(OR 1.93;P<0.001);美沙酮OR 14.98(P<0.001)。
- 海洛因、芬太尼及合成非药品类阿片报告绝对增加512%(r=0.92;P<0.001),与严重效应相关(OR 20.1;P<0.001)。
- 作者认为暴露下降可能因医疗人员报告不足而夸大,但仍强调需加强中毒预防策略。
适用人群与场景
- 2016至2023年美国毒物中心报告的1月龄至6岁患儿单物质阿片暴露。
研究设计与关键结果
- 回顾性研究分析34,632例1月龄至6岁患儿单物质阿片暴露报告,96.7%为意外暴露,中位年龄2.0岁(IQR 1.33-3.0岁)。
- 报告暴露总数下降57.5%(r=-0.96;P<0.001),但死亡和严重效应绝对增加300%(r=0.96;P<0.001)。
- 导致轻微、无效应、未随访或无法随访的暴露下降66.2%(r=-0.99;P<0.001)。
- 丁丙诺啡最常见,占报告暴露的23.4%;丁丙诺啡(OR 1.93;P<0.001)和美沙酮(OR 14.98;P<0.001)与其他处方药(OR 1)相比与严重效应风险增加相关。
- 海洛因、芬太尼及合成非药品类阿片报告随时间绝对增加512%(r=0.92;P<0.001),且与严重效应相关(OR 20.1;P<0.001)。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:作者认为57.5%的下降可能因医疗人员报告不足而夸大,但假定下降在整个数据集中均衡,因此对其他分析点无差异化影响。
对床旁实践的改变
- 作者认为研究强调持续需要加强中毒预防策略。
- 作者指出涉及的阿片类药物已从氢可酮、羟考酮和曲马多转向芬太尼和丁丙诺啡。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: The objective of this study was to update and expand on previous studies of opioid exposures among young children reported to America's Poison Centers®, and to describe how fentanyl and medications for opioid use disorder have contributed.
METHODS: This retrospective study investigated 34,632 reports of single-substance opioid exposure from 2016 to 2023 involving pediatric patients aged one month to six years old. Descriptive statistics, tests for data normality, and significance testing were performed where applicable.
RESULTS: Of 34,632 reported exposures, 96.7% were unintentional. The median age of exposure was 2.0 years (IQR 1.33-3.0 years). Reported exposures decreased by 57.5% over the study period (r = -0.96; P <0.001). However, there was a 300% absolute increase in deaths and major effects (r = 0.96; P <0.001). Exposures resulting in minor, no effect, not followed, or unable to follow decreased 66.2% (r = -0.99; P <0.001). Buprenorphine was most frequently involved, comprising 23.4% of reported exposures. Buprenorphine (OR 1.93; P <0.001) and methadone (OR 14.98; P <0.001) were associated with an increased risk of severe effects when compared to other prescription drugs (OR: 1). There was an absolute increase of 512% over time in reports of heroin, fentanyl, synthetic non-pharmaceutical opioids (r = 0.92; P <0.001), which were also associated with severe effects (OR 20.1; P <0.001).
DISCUSSION: Pediatric opioid exposures have previously been reported to be relatively stable. It is likely the 57.5% reduction is exaggerated due to underreporting from health care providers. However, decreases in exposures are presumed to be balanced throughout the dataset and, therefore, without differential impact on other points of analysis. Our study highlights the continued need for enhanced poisoning prevention strategies.
CONCLUSIONS: The relative severity of poisonings reported to poison centers worsened over the study period. The opioids implicated have shifted away from hydrocodone, oxycodone, and tramadol, and towards fentanyl and buprenorphine.
参考来源
- Rosen PE, Ramdin C, Leonard J, et al. Trends in opioid exposures among young children reported to United States poison centers from 2016 to 2023. Clin Toxicol (Phila). 2024. PMID: 39316461. doi:10.1080/15563650.2024.2401598
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。